Drug policy and the public good
T Babor - 2010 - books.google.com
Drug use represents a significant burden to public health through disease, disability and
social problems, and policy makers are becoming increasingly interested in how to develop …
social problems, and policy makers are becoming increasingly interested in how to develop …
Interventions to improve safe and effective medicines use by consumers: an overview of systematic reviews
Background Many systematic reviews exist on interventions to improve safe and effective
medicines use by consumers, but research is distributed across diseases, populations and …
medicines use by consumers, but research is distributed across diseases, populations and …
[图书][B] WHO guideline on country pharmaceutical pricing policies
World Health Organization - 2020 - apps.who.int
Country Pharmaceutical Pricing Policies Page 1 ACCESS TO MEDICINES, VACCINES AND
PHARMACEUTICALS WHO Guideline on Country Pharmaceutical Pricing Policies WHO guideline …
PHARMACEUTICALS WHO Guideline on Country Pharmaceutical Pricing Policies WHO guideline …
[HTML][HTML] Physician awareness of drug cost: a systematic review
GM Allan, J Lexchin, N Wiebe - PLoS medicine, 2007 - journals.plos.org
Background Pharmaceutical costs are the fastest-growing health-care expense in most
developed countries. Higher drug costs have been shown to negatively impact patient …
developed countries. Higher drug costs have been shown to negatively impact patient …
Cost-containment policies in public pharmaceutical spending in the EU
G Carone, C Schwierz, A Xavier - Available at SSRN 2161803, 2012 - papers.ssrn.com
This paper presents and evaluates pharmaceutical policies in the EU aimed at the rational
use of medicines and at keeping pharmaceutical spending under control. Policy makers are …
use of medicines and at keeping pharmaceutical spending under control. Policy makers are …
[PDF][PDF] The impact of pharmaceutical pricing and reimbursement policies on generics uptake: implementation of policy options on generics in 29 European countries …
S Vogler - Generics and Biosimilars Initiative Journal, 2012 - gabi-journal.net
All European countries are facing growing pharmaceutical expenditure, particularly in public
expenditure [3] given that Europe has a comparatively higher coverage of publicly funded …
expenditure [3] given that Europe has a comparatively higher coverage of publicly funded …
Pharmaceutical policies: effects of cap and co‐payment on rational drug use
A Austvoll‐Dahlgren, M Aaserud… - Cochrane database …, 1996 - cochranelibrary.com
Background Growing expenditures on prescription drugs represent a major challenge to
many health systems. Cap and co‐payment (direct cost‐share) policies are intended as an …
many health systems. Cap and co‐payment (direct cost‐share) policies are intended as an …
Policies to promote use of generic medicines in low and middle income countries: a review of published literature, 2000–2010
WA Kaplan, LS Ritz, M Vitello, VJ Wirtz - Health policy, 2012 - Elsevier
OBJECTIVE: Review the literature on the impact of policies designed to enhance uptake of
generic medicines in low and middle income countries (LMICs). METHODS: We searched …
generic medicines in low and middle income countries (LMICs). METHODS: We searched …
Impact of European pharmaceutical price regulation on generic price competition: a review
J Puig-Junoy - Pharmacoeconomics, 2010 - Springer
Although economic theory indicates that it should not be necessary to intervene in the
generic drug market through price regulation, most EU countries intervene in this market …
generic drug market through price regulation, most EU countries intervene in this market …
[HTML][HTML] What impact do prescription drug charges have on efficiency and equity? Evidence from high-income countries
MC Gemmill, S Thomson, E Mossialos - International journal for equity in …, 2008 - Springer
As pharmaceutical expenditure continues to rise, third-party payers in most high-income
countries have increasingly shifted the burden of payment for prescription drugs to patients …
countries have increasingly shifted the burden of payment for prescription drugs to patients …